Preferred Label : aflibercept;

MeSH note : consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders;

CISMeF synonym : AVE 0005; AVE 005; ZIV-aflibercept; eylea; zaltrap;

MeSH synonym : VEGF trap - regeneron; VEGF Trap-Eye; VEGF-Trap;

MeSH hyponym : AVE0005; AVE-0005; AVE005; AVE-005;

Is substance : O;

UNII : 15C2VL427D;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/afqlir
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
aflibercept
aflibercept
biosimilar pharmaceuticals

---
https://www.ema.europa.eu/en/medicines/human/EPAR/eydenzelt
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept

---
https://www.ema.europa.eu/en/medicines/human/EPAR/opuviz
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
aflibercept
aflibercept
biosimilar pharmaceuticals

---
https://www.ema.europa.eu/en/medicines/human/EPAR/ahzantive
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept

---
https://www.ema.europa.eu/en/medicines/human/EPAR/baiama
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept

---
https://ansm.sante.fr/tableau-marr/aflibercept
2025
false
false
false
France
French
guidelines for drug use
patients guideline
aflibercept
recombinant fusion proteins
receptors, vascular endothelial growth factor
Drug-Related side effects and adverse reactions
signs and symptoms
intravitreal injections
video recording
intravitreal injections
sound

---
https://www.has-sante.fr/jcms/p_3535158/fr/eylea-aflibercept-oedeme-maculaire-diabetique-omd
2024
false
false
false
France
aflibercept
adult
treatment outcome
insurance, health, reimbursement
vision disorders
intravitreal injections
evaluation of the transparency committee
aflibercept
macular edema
diabetes complications

---
https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept
aflibercept
biosimilar pharmaceuticals

---
https://www.has-sante.fr/jcms/p_3563526/fr/eylea-aflibercept-degenerescence-maculaire-liee-a-l-age-oedeme-maculaire-diabetique
2024
false
false
false
France
diabetes complications
Visual acuity reduced
aflibercept
treatment outcome
insurance, health, reimbursement
intravitreal injections
vascular endothelial growth factor a
evaluation of the transparency committee
aflibercept
macular edema
wet macular degeneration

---
https://www.has-sante.fr/jcms/p_3289074/fr/eylea-aflibercept-omd
2021
false
false
false
France
evaluation of the transparency committee
aflibercept
eylea
aflibercept

---
https://ansm.sante.fr/informations-de-securite/eylea-40-mg-ml-aflibercept-en-injection-intravitreenne-risque-plus-eleve-daugmentation-de-la-pression-intraoculaire-a-la-suite-de-lutilisation-de-la-seringue-preremplie
2021
false
false
false
France
French
pharmacovigilance note
intravitreal injections
aflibercept
ocular hypertension
aflibercept
Pre-filled Syringe
drug compounding
intravitreal injections
aflibercept
guidelines for drug use
continuity of patient care
Inappropriate preparation of medication
recombinant fusion proteins
receptors, vascular endothelial growth factor
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
https://www.has-sante.fr/portail/jcms/c_2800955/fr/place-dans-la-strategie-therapeutique-de-lucentis-eylea-et-de-leurs-comparateurs-cliniquement-pertinents-dans-la-forme-neovasculaire-humide-de-la-dmla
2017
false
false
false
France
French
evaluation of the transparency committee
intravitreal injections
wet macular degeneration
comparative effectiveness research
vascular endothelial growth factor a
Ranibizumab
ranibizumab
treatment outcome
aflibercept
aflibercept
Bevacizumab
angiogenesis inhibitors
risk management
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2589764/fr/eylea
2016
false
France
French
macular edema
retinal vein occlusion
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2671791/fr/eylea
http://www.has-sante.fr/portail/jcms/c_2671791/fr/eylea-aflibercept-anti-vegf
2016
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
adult
treatment outcome
aflibercept
aflibercept
aflibercept
intravitreal injections
choroidal neovascularization
myopia
visual acuity
vision disorders
insurance, health, reimbursement
vascular endothelial growth factors
recombinant fusion proteins
receptors, vascular endothelial growth factor
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
http://www.has-sante.fr/portail/jcms/c_2025589/fr/eylea
http://www.has-sante.fr/portail/jcms/c_2025589/fr/eylea-aflibercept-anti-vegf
2015
false
France
French
macular edema
guidelines for drug use
diabetic retinopathy
diabetes complications
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_1751177/fr/eylea
2014
false
France
French
macular edema
retinal vein occlusion
guidelines for drug use
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
randomized controlled trials as topic
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60089217
2014
false
false
false
France
French
package leaflet
summary of product characteristics
aflibercept
perfusion
perfusion, nos
solution, nos
aflibercept
solutions
perfusion
solutions
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
https://www.ema.europa.eu/medicines/human/EPAR/Zaltrap
2013
false
United Kingdom
French
English
aflibercept
FOLFIRI-Ziv-aflibercept Regimen
aflibercept
drug approval
europe
treatment outcome
infusions, intravenous
adult
colorectal neoplasms
neoplasm metastasis
antineoplastic combined chemotherapy protocols
pregnancy
breast feeding
antineoplastic agents
antineoplastic agents
receptors, vascular endothelial growth factor
Placenta Growth Factor
vascular endothelial growth factor a
vascular endothelial growth factor b
randomized controlled trials as topic
survival analysis
drug evaluation, preclinical
summary of product characteristics
package leaflet
syndication feed
drug evaluation
drug compounding
pregnancy proteins
recombinant fusion proteins
recombinant fusion proteins
aflibercept

---
http://www.has-sante.fr/portail/jcms/c_1554433/fr/eylea
2013
false
France
French
guidelines for drug use
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
wet macular degeneration
aflibercept
vascular endothelial growth factor a
Placenta Growth Factor
treatment outcome
randomized controlled trials as topic
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins
pregnancy proteins
comparative study

---
http://www.has-sante.fr/portail/jcms/c_1638052/fr/zaltrap
http://www.has-sante.fr/portail/jcms/c_1638051/fr/zaltrap-24072013-avis-ct12847
2013
false
France
French
aflibercept
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
guidelines for drug use
evaluation of the transparency committee
aflibercept
aflibercept
IFL protocol
antineoplastic combined chemotherapy protocols
colorectal neoplasms
adult
neoplasm metastasis
Outcome Assessment, Health Care
vascular endothelial growth factors
infusions, intravenous
treatment outcome
clinical trials, phase iii as topic
survival analysis
recombinant fusion proteins
recombinant fusion proteins

---
http://www.meddispar.fr/Medicaments/EYLEA-40-B-1/(type)/letter/(value)/E/(cip)/3400926783679
2013
France
French
drug information
aflibercept
aflibercept
drug prescriptions
legislation, drug
intravitreal injections
wet macular degeneration
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
https://www.ema.europa.eu/medicines/human/EPAR/Eylea
2012
false
United Kingdom
English
French
aflibercept
drug approval
europe
treatment outcome
aflibercept
adult
wet macular degeneration
summary of product characteristics
package leaflet
drug evaluation
syndication feed
vascular endothelial growth factor a
Placenta Growth Factor
intravitreal injections
recombinant fusion proteins
recombinant fusion proteins
pregnancy
breast feeding
fertility
randomized controlled trials as topic
drug evaluation, preclinical
pregnancy proteins
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
comparative study
aflibercept

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.